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OBJECTIVE—Retinoid X receptors (RXRs) are members of the
nuclear hormone receptor superfamily and are thought to be key
regulators in differentiation, cellular growth, and gene expres-
sion. Although several experiments using pancreatic -cell lines
have shown that the ligands of nuclear hormone receptors
modulate insulin secretion, it is not clear whether RXRs have any
role in insulin secretion.
RESEARCH DESIGN AND METHODS—To elucidate the
function of RXRs in pancreatic -cells, we generated a double-
transgenic mouse in which a dominant-negative form of RXR
was inducibly expressed in pancreatic -cells using the Tet-On
system. We also established a pancreatic -cell line from an
insulinoma caused by the -cell–speciﬁc expression of simian
virus 40 T antigen in the above transgenic mouse.
RESULTS—In the transgenic mouse, expression of the domi-
nant-negative RXR enhanced the insulin secretion with high
glucose stimulation. In the pancreatic -cell line, the suppression
of RXRs also enhanced glucose-stimulated insulin secretion at a
high glucose concentration, while 9-cis-retinoic acid, an RXR
agonist, repressed it. High-density oligonucleotide microarray
analysis showed that expression of the dominant-negative RXR
affected the expression levels of a number of genes, some of
which have been implicated in the function and/or differentiation
of -cells.
CONCLUSIONS—These results suggest that endogenous RXR
negatively regulates the glucose-stimulated insulin secretion.
Given these ﬁndings, we propose that the modulation of
endogenous RXR in -cells may be a new therapeutic ap-
proach for improving impaired insulin secretion in type 2
diabetes. Diabetes 59:2854–2861, 2010
T
he nuclear hormone receptor superfamily plays
essential roles in various aspects of biological
regulation, such as differentiation, cellular
growth, and metabolism. The retinoid X recep-
tors (RXRs) play a unique and central role in the activity of
many members of this superfamily. They function as an
obligate heterodimeric partner for retinoic acid receptors
(RARs), thyroid hormone receptor, vitamin D receptor,
peroxisome proliferator–activated receptors (PPARs),
liver X receptors (LXRs), farnesoid X receptor, and others
(1). Because of this unique position within the superfam-
ily, the modulation of the activity of RXRs is considered to
cause a broad spectrum of effects (2,3).
In pancreatic -cells, there are several lines of evidence
from in vitro studies that nuclear receptors are involved in
the insulin secretory mechanism. Retinoic acid affects the
expression of the glucokinase and preproinsulin genes and
promotes insulin secretion in RIN-m5F cells (4,5) and in
isolated islets (6). In INS-1 cells, both 9-cis-retinoic acid
(9cRA), a ligand of RXRs, and all-trans-retinoic acid
(ATRA), a ligand of RARs, increase insulin secretion, and
ATRA raises GLUT2 mRNA (7). In contrast, 9cRA and a
high concentration of rosiglitazone, a ligand of PPAR-,
are reported to inhibit glucose-stimulated insulin secretion
(GSIS) in INS-1 cells (7), suggesting that the PPAR/RXR
heterodimer is inhibitory to insulin secretion in -cells.
Recent reports showed that the co-overexpression of
PPAR- and RXR- in INS-1 cells potentiated glucose-
induced insulin secretion, whereas the co-overexpression
of PPAR- and RXR- in INS-1 cells attenuated it (8).
Although these results suggest that RXR plays a role in
regulating the insulin secretory machinery of -cells, it is
still controversial whether RXR has a direct effect on
insulin secretion.
RXR is composed of three family members—RXR-,- ,
and -—that have redundant roles (8–10). Therefore, it is
necessary to disrupt the genes for all three RXR members
to inactivate RXR function. Considering the practical
difﬁculty of a -cell–speciﬁc knockout of all three genes,
we took another approach using a dominant-negative form
of RXR. RXRC2, which lacks the ligand-binding domain,
is known to act as a dominant-negative receptor and to
inhibit the ligand-dependent transcriptional activation of
target genes by homodimerized and heterodimerized RXRs
(11). To investigate the in vivo function of RXR in -cells,
we generated a double-transgenic (Tg) mouse: one trans-
gene expresses reverse tetracycline-regulated transactiva-
tor (rtTA) under the insulin promoter, and the other
expresses RXRC2 under the tetracycline-responsive
TetO promoter. In this Tg mouse line, the addition of
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RXRC2 in the -cells. The tetracycline-treated Tg mice
showed elevated glucose tolerance, and islets isolated
from these mice also showed enhanced GSIS.
To examine the role of RXR in -cells, we established
-cell lines (dnRXR-MIN6 cells) from an insulinoma that
developed in a triple-Tg mouse harboring the SV40 T
antigen gene under the insulin promoter in addition to the
two transgenes for RXRC2 expression. Using this cell
line, we conﬁrmed that the suppression of RXR enhanced
the glucose-stimulated insulin secretion at a high glucose
concentration in vitro. High-density oligonucleotide mi-
croarray analysis showed that the expression of a number
of genes was affected by the suppression of RXR. Our
ﬁndings suggest that modulating the activity of the endog-
enous RXRs in -cells may provide a novel therapeutic
approach for improving impaired insulin secretion in type
2 diabetes.
RESEARCH DESIGN AND METHODS
Generation of double-Tg mice. To generate Tg mice in which the expres-
sion of a dominant-negative form of RXR could be induced in -cells, we
designed two transgenes to use the Tet-On system (12–14). The ﬁrst transgene,
Ins-rtTA, carried the reverse tetracycline-regulated transactivator (rtTA) gene
under the human insulin promoter (Fig. 1A). The second transgene, TetO-
RXRC2, carried the RXRC2 cDNA, which encodes a dominant-negative
form of mouse RXR, lacking 20 conserved COOH-terminal amino residues of
the ligand-binding and dimerization domain (11), and the human growth
hormone gene, including the polyadenylation signal, following the TetO
promoter (Fig. 1B). Tg mice were generated by DNA microinjection into the
pronuclei of fertilized eggs of C57BL/6J. Tg founder mice were identiﬁed by
PCR analyses of the genomic DNA obtained from tail tips. In the Ins-rtTA/
TetO-RXRC2 double-Tg mice, the islet-speciﬁc expression of rtTA and
inducible expression of RXRC2 were conﬁrmed by RT-PCR and immuno-
histochemical analyses. For doxycycline (Dox) treatment, doxycycline hydro-
chloride (Sigma-Aldrich, St. Louis, MO) was dissolved in water at a
concentration of 1 mg/ml, and this solution was used as the drinking water for
the double-Tg mice.
Oral glucose tolerance test. An oral glucose tolerance test (OGTT) was
performed twice on the same groups of the double-Tg mice: after 2 weeks of
Dox treatment (Dox On) and 2 weeks after the withdrawal of Dox treatment
(Dox Off). The Tg mice were fasted overnight for 16 h followed by oral
administration of glucose (2 g/kg body wt). Blood samples were collected by
retro-orbital sinus puncture before (0 min) and 10, 30, 60, and 120 min after
glucose administration. Plasma samples were obtained by centrifugation at
4°C and were stored at 80°C until analysis. The plasma glucose and insulin
concentrations were measured using a blood glucose test kit (Glucose
CII-test; Wako Pure Chemicals, Osaka, Japan) and an enzyme-linked immu-
nosorbent assay (ELISA) kit (Morinaga, Yokohama, Japan), respectively.
Measurement of insulin secretion and insulin content. Double-Tg mice
with or without 2 weeks of Dox treatment were killed, and their islets were
isolated according to a previously described method (15). The isolated islets
were cultured in RPMI medium with 11 mmol/l glucose, 10% FBS, and
antibiotics. For the islets from Dox-treated Tg mice, 5 g/ml Dox was added
to the medium. After cultivation for 24 h, 10 mol/l 9cRA was added to the
culture of half of the islets from Dox-treated Tg mice and that from
Dox-untreated Tg mice. After further cultivation for 20 h, the islets of a similar
size were washed with Krebs-Ringer bicarbonate buffer (KRBB) containing
0.2% BSA and transferred to microcentrifuge tubes (10 islets per tube; n  5–6
for each group). They were then cultured in KRBB containing 0.2% BSA with
3, 9, or 27 mmol/l glucose for 60 min, and the supernatant was collected and
assayed for insulin using an ELISA kit (Mercodia, Uppsala, Sweden). For
measurement of insulin content, double-Tg mice with or without 2 weeks of
Dox treatment were killed and their pancreases were isolated. Insulin was
extracted from them with acid ethanol and measured by immunoassay as
described above.
Establishment of the dnRXR-MIN6 -cell lines. To establish -cell lines
with inducible RXRC2 expression, Ins-rtTA/TetO-RXRC2 double-Tg
mice were mated with IT-6 Tg mice. IT-6 Tg mice bear the SV40 T antigen gene
under the human insulin promoter and were originally used to establish MIN6
cells, a -cell line that retains GSIS (16). The resulting triple-Tg mice were
identiﬁed by the PCR analysis of genomic DNA obtained from the tail tips.
Pancreatic -cell lines were generated from 22 insulinomas isolated from the
triple-Tg mice at the age of 9 weeks. Finally, two clones with good GSIS and
stable induction of RXRC2 by Dox were selected (named dnRXR-MIN6)
and used for experiments.
Western blotting and immunocytochemistry. The total protein was ex-
tracted from dnRXR-MIN6 cells after cultivation with or without Dox for 4
days and subjected to Western blotting using a mouse anti-mouse RXR
monoclonal antibody (MA3-812 [clone MOK13.17]; Afﬁnity Bioreagents,
Golden, CO) that detects RXRC2 (11) and a horseradish peroxidase–
conjugated second antibody. Detection was done by enhanced chemilumines-
cence (ECL kit; Amersham, Arlington Heights, IL). Immunocytochemistry was
performed with dnRXR-MIN6 cells. The cultured cells were washed with PBS
and ﬁxed in 4% paraformaldehyde for 10 min. After ﬁxation, the cells were
rinsed with PBS, incubated for 5 min in 1% Triton X-100, and, after a second
wash, incubated in a blocking reagent. The samples were incubated with the
ﬁrst antibody for 60 min at room temperature, washed with PBS, and then
incubated with the second antibody for 60 min at room temperature. The
primary antibody was a mouse anti-mouse RXR antibody (MOK13.17); the
secondary antibody was Alexa Fluor 488–conjugated anti-mouse IgG1 (Mo-
lecular Probes, Eugene, OR).
Immunohistochemical analyses. Immunohistochemistry was performed
with frozen sections or parafﬁn sections of pancreatic tissue. The 8-m-thick
frozen sections were placed on slides and ﬁxed in cold acetone for 10 min.
Pancreatic tissue was also ﬁxed in 4% paraformaldehyde overnight and
processed for parafﬁn embedding. Sections of parafﬁn-embedded pancreatic
tissue (3–5 m thick) were deparafﬁnized and dehydrated. The frozen and
parafﬁn sections were incubated with 3% normal goat serum in PBS containing
10% Blocking One (Nacalai Tesque, Kyoto, Japan) for 60 min at room
temperature. The sections were then incubated with the ﬁrst antibody at 4°C
overnight and with a ﬂuorescein-conjugated second antibody for 60 min at
room temperature. After each antibody incubation, the sections were washed
in PBS for 5 min with three changes. The ﬁrst antibodies were guinea pig
anti-insulin antibody (Dako, Carpentaria, CA), rabbit anti-VP16 antibody for
the detection of rtTA, and mouse anti-mouse RXR antibody. The secondary
antibodies were Alexa Fluor 594–conjugated anti-guinea pig IgG, Alexa Fluor
488–conjugated anti-rabbit IgG, and Alexa Fluor 488–conjugated anti-mouse
IgG1 (Molecular Probes). The sections were observed by ﬂuorescence micros-
copy (Olympus, Tokyo, Japan).
RT-PCR and real-time PCR analyses. The total RNA was extracted from
isolated islets and dnRXR-MIN6 cells after they were cultivated with or without
Dox for 4 days by the acid guanidinium-phenol-chloroform method and was
subjected to cDNA synthesis using ReverTra Ace  (Toyobo, Tokyo, Japan) (17).
The cDNA was subjected to PCR with the following primers: rtTA forward
primer, 5-CGCATTAGAGCTGCTTAAT-3 and backward primer, 5-TGACTTAG
TAAAGCACATCT-3; RXR forward primer, 5-GCTGCTGTTACGTCTTCCTG-3
and backward primer 5-AGCGTTGTCAAAAAGCCTGG-3 that binds to the
sequence within the second exon of the human growth hormone gene in the
TetO-RXRC2 transgene; and HPRT forward primer, 5-CTCGAAGTGTTG
GATACAGG-3and backward primer, 5-TGGCCTATAGGCTCATAGTG-3. These
Tet O promoter hGHpA
RXRβ∆C2 cDNA
Wild type RXRβ cDNA  
DBD
human insulin promoter rtTA cDNA pA
DBD LBD
LBD
A
B
Ins-rtTA
TetO-RXRβ∆C2
∆20 AA
FIG. 1. DNA constructs used to generate transgenic mice. Two trans-
genes were constructed to enable the Tet-On system to work: the
transgene termed Ins-rtTA (A) carried the reverse tetracycline-regu-
lated transactivator (rtTA) gene under the human insulin promoter,
and the other transgene, termed TetO-RXRC2 (B), carried the
RXRC2 cDNA, which encodes a dominant-negative form of mouse
RXR lacking 20 conserved COOH-terminal amino residues of the
ligand-binding and dimerization domain, following the TetO promoter.
DBD, DNA-binding domain; LBD, ligand-binding domain. (A high-qual-
ity color representation of this ﬁgure is available in the online issue.)
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appropriate PCR products from products ampliﬁed from contaminating genomic
DNA. Real-time PCR was performed on an ABI Prism 7300 Sequence Detection
System (Applied Biosystems, Foster City, CA), using the SYBR Green PCR core
reagents detection system (Applied Biosystems). The primer sequences are
shown in supplementary Table 1. PCR was performed with an initial step of 10 s
at 95°C followed by 40 cycles of5sa t95°C and 31 s at 60°C. The levels of targeted
gene expression were normalized to that of -actin. Statistical analysis was
performed by a Student t test.
Glucose-stimulated insulin secretion in vitro. dnRXR-MIN6 cells were
cultured in 24-well plates with Dulbecco’s modiﬁed Eagle’s medium in the
presence or absence of 2 g/ml Dox for 4 days. In some experiments, 5 mol/l
9cRA was added for the last 2 days of culture. Cells were starved in KRBB
containing 0.1% BSA and 3 mmol/l glucose for 1 h, and wells were replenished
with the same buffer twice. Then, cells were stimulated with 3, 10, or 25
mmol/l glucose in 500 l KRBB containing 0.1% BSA for 1 h. The supernatants
were collected and assayed for insulin using an ELISA kit. The values were
normalized to the protein amount of each well. Statistical analysis was
performed by a Student t test.
Microarray analysis. Total RNA was extracted by the acid guanidinium-
phenol-chloroform method from dnRXR-MIN6 cells, after they were cultivated
with or without Dox for 4 days. The quality of the puriﬁed total RNA was
examined with an Agilent 2100 Bioanalyzer. We used 500 ng veriﬁed RNA to
obtain cyanine 3 (Cy3)- or cyanine 5 (Cy5)-labeled cRNA using a Low RNA
Input Fluorescent Linear Ampliﬁcation Kit (Agilent), following the protocols
recommended by the manufacturer. The cRNA was puriﬁed with RNeasy mini
spin columns (Qiagen), and then 0.75 g each of the Cy3- and Cy5-labeled
cRNAs were combined, fragmented, and used for hybridization to a high-
density oligonucleotide microarray (Affymetrix). For the ﬁrst hybridization,
we used RNA from dnRXR-MIN6 Dox(	) (Cy5) and dnRXR-MIN6 Dox()
(Cy3), and for the second, we used RNA from dnRXR-MIN6 Dox(	) (Cy3) and
dnRXR-MIN6 Dox() (Cy5). We quantiﬁed the image using Agilent Feature
Extraction Software.
RESULTS
Islet-speciﬁc overexpression of RXRC2 in Ins-
rtTA/TetO-RXRC2 double-Tg mice. To achieve tet-
racycline-inducible expression of the RXRC2 gene in
vivo, two types of Tg mouse were generated. The ﬁrst Tg
mouse, Ins-rtTA, expressed rtTA under the human insulin
promoter (Fig. 1A). One line was obtained, and the speciﬁc
expression of rtTA in the pancreas of these mice was
conﬁrmed by RT-PCR analysis (Fig. 2A). Immunohisto-
chemical staining of the pancreas using an anti-VP16
antibody for the detection of rtTA conﬁrmed the islet-
speciﬁc expression of rtTA, while the pancreas of non-Tg
control mice did not show speciﬁc staining (Fig. 2B). The
second Tg mouse was termed TetO-RXRC2 (Fig. 1B).
To select one line out of the ﬁve obtained, an adenoviral
vector AdV-rtTA, which expressed the rtTA gene under the
control of the ubiquitous promoter (18), was injected into
one mouse of each TetO-RXRC2 Tg line via the tail vein.
After 1 week of Dox treatment, the isolated livers were
subjected to Western blotting analysis with an anti-RXR
antibody. One line in which RXRC2 was properly in-
duced in the liver was selected. Finally, the Ins-rtTA/TetO-
RXRC2 double-Tg mice were generated as described in
RESEARCH DESIGN AND METHODS. These mice are called domi-
nant-negative RXR (dnRXR) Tg mice in the following
study.
RT-PCR analysis showed that RXRC2 was expressed
only in the islets of the Dox-treated double-Tg mice (Fig.
2C). Immunohistochemical analysis showed that the nu-
clei of the islet -cells of Dox-treated dnRXR Tg mice
[Dox(	)] were more strongly stained with an anti-RXR
antibody than those of the Dox-untreated mice [Dox()]
(Fig. 2D). The weak staining of the latter sample was
probably due to the expression of endogenous RXR,
because the pancreas samples from non-Tg mice were
similarly stained. These ﬁndings indicated that islet-spe-
ciﬁc expression of RXRC2 was inducible by Dox in the
dnRXR Tg mice.
Suppression of RXRs increases the GSIS in vivo. To
investigate the effect of dnRXR expression in -cells on
glucose homeostasis, OGTTs were performed after 2
weeks of Dox treatment (Dox On) and 2 weeks after the
withdrawal of Dox treatment (Dox Off) (Fig. 3A). Interest-
ingly, the dnRXR Tg mice showed signiﬁcantly improved
glucose tolerance under the expression of the dnRXR
(Dox On) compared with after the withdrawal of the Dox
treatment (Dox Off) (Fig. 3B). Plasma insulin levels at 10
min after glucose administration were signiﬁcantly higher
under the Dox treatment (Dox On) compared with after
the withdrawal of the Dox treatment (Dox Off) (Fig. 3C).
The non-Tg control mice showed no signiﬁcant change
in the glucose tolerance with Dox treatment (data not
shown). In a separate experiment, we examined whether
the Dox treatment affected the body weight of the dnRXR
Tg mice. Eight-week-old dnRXR Tg mice were maintained
with or without Dox treatment (n  5 each) for 2 weeks,
and their body weights were measured. The result showed
that there were no signiﬁcant changes in the body weight
between Dox-treated and Dox-untreated mice. Therefore,
the improved glucose tolerance seen under the expression
of the dnRXR was mostly due to the improved response
of -cells to glucose.
We then examined the GSIS of isolated islets. In this
analysis, the effect of 9cRA, an RXR agonist, was also
examined. At 9 and 27 mmol/l glucose, the insulin secre-
tion of the Dox(	) islets was signiﬁcantly higher (
1.3-
fold) than that of the Dox() islets (Fig. 4A). Interestingly,
9cRA treatment signiﬁcantly reduced the insulin secretion
at the high glucose concentration both from the Dox(	)
and Dox() islets. This effect of 9cRA was not observed at
3 or 9 mmol/l glucose.
To examine whether expression of the dnRXR affected
the transcription of insulin genes, the mRNA for the two
insulin genes was quantiﬁed. The total RNA of islets
isolated from Dox-treated and Dox-untreated mice was
subjected to semi-quantitative RT-PCR analyses for the
insulin 1 and insulin 2 genes. The results showed no
signiﬁcant differences in the expression level of these
genes between the Dox(	) and Dox() islets (data not
shown). We further examined whether expression of
dnRXR affected the insulin content of the pancreas.
Pancreases were isolated from Dox-treated and Dox-
untreated mice, and insulin content was measured. No
signiﬁcant differences were observed in the insulin con-
tent between the Dox(	) and Dox() pancreases (Fig.
4B). These results suggested that the expression of the
dnRXR affected insulin secretion through a mechanism
occurring after insulin production.
dnRXR increases the GSIS in a -cell line. To exam-
ine the molecular mechanism underlying the elevated
GSIS of islets cells by the expression of the dnRXR,w e
sought to establish -cell lines with Tet-inducible
RXRC2 expression using a triple-Tg mouse strategy
involving the IT-6 Tg mouse expressing the SV40 T antigen
gene under the human insulin promoter (16). A total of 22
-cell lines were established from each insulinoma devel-
oped in the pancreases of the triple-Tg mice and were
tested for GSIS. Most lines exhibited appropriate GSIS.
Two lines (19 and 21) were ultimately selected, termed
dnRXR-MIN6 cells, and subjected to further analyses. Both
clones showed similar results, and the data with clone 19
were presented. In dnRXR-MIN6 cells, the stable expres-
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were conﬁrmed by RT-PCR analysis, Western blotting, and
immunocytochemistry (Fig. 5A–C). We also conﬁrmed that
Dox treatment affected neither the proliferation nor apop-
tosis of dnRXR-MIN6 cells (supplementary Figs. 1 and 2).
After incubation with or without Dox for 4 days,
insulin secretion was measured at different glucose
concentrations. In this analysis, the effect of 9cRA was
also examined. At 10 and 25 mmol/l glucose, the insulin
secretion of the Dox-treated cells was signiﬁcantly
higher (1.5-fold) than that of the Dox-untreated cells
(Fig. 5D). Interestingly, 9cRA treatment signiﬁcantly
reduced the insulin secretion at the high glucose con-
centration from both Dox-treated and untreated dnRXR-
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D
FIG. 2. Islet-speciﬁc induction of RXRC2 in the Ins-rtTA/TetO-RXRC2 double-Tg mice. The total RNA of the pancreas and other organs was
subjected to RT-PCR analyses. The rtTA transgene expression was detected only in the pancreas samples from three different Tg mice and not
in the other organs or in the non-Tg pancreas (A, upper panel). Hypoxanthine-guanine phosphoribosyltransferase (HPRT) was used as an internal
control (A, lower panel). Immunohistochemistry for rtTA in the pancreas of the Ins-rtTA Tg mouse (B, right panel) or a non-Tg mouse (B, left
panel) is shown. The islets in the pancreas (arrowhead) of the Tg mouse were stained by an anti-rtTA antibody. The scale bars represent 100
m. By RT-PCR, expression of the RXRC2 transgene was detected in the islets from two different double-Tg mice treated with Dox, but not
in those from two untreated mice (C). D: Immunohistochemistry of the pancreas of an Ins-rtTA/TetO-RXRC2 double-Tg mouse using an
anti-RXR antibody. Magniﬁed views of the islets before (left panel) and after (right panel) Dox treatment are shown. Lower panels show double
staining of the same islets with anti-RXR (green) and anti-insulin (red) antibodies. Dox treatment induced a high-level expression of the
dnRXR in the islet -cells of the double-Tg mouse. Scale bars represent 100 m. (A high-quality digital representation of this ﬁgure is available
in the online issue.)
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10 mmol/l glucose.
cDNA microarray analysis. RXRs function as transcrip-
tion factors in a homodimeric or heterodimeric form.
Therefore, the induced expression of the dnRXR must
inﬂuence the transcriptional levels of various target genes,
some of which are assumed to be related to the regulation
of insulin secretion in -cells. We used high-density (Af-
fymetrix) oligonucleotide microarrays to identify genes
that were differentially expressed by the Dox-treated and
untreated dnRXR-MIN6 cells. To correct for dye bias and
exclude false-positive genes, dye swapping and subse-
quent normalization were performed. Supplementary Ta-
bles 2 and 3 list the genes for which a mean twofold or
greater change in transcript level was demonstrated in the
dye-swap experiment. We noted that the list included
genes that might be related to the regulation of insulin
secretion. We selected some of these genes to analyze by
real-time PCR (Fig. 6). The results showed that these
genes were clearly down- or upregulated by the Dox
treatment, consistent with the microarray analysis.
DISCUSSION
Several studies have shown that RXR agonists have a
beneﬁcial effect on glucose tolerance in type 2 diabetes.
The RXR agonist LG100268 was reported to protect the
insulin secretory capacity in the db/db mouse, a model for
this disease (19,20). A recent report also showed that
LG101506, a heterodimer-selective RXR stimulator, also
has insulin-sensitizing activity in the fa/fa rat (21). Al-
though these data suggest that RXR agonists are beneﬁcial
for glucose tolerance, there has been no direct evidence
for an effect of RXR on the insulin secretory mechanism in
-cells. Thus, to elucidate the function of RXRs in -cells,
we produced a Tg mouse and established -cell lines in
which conditionally inducible dnRXR gene expression was
achieved.
The dnRXR Tg mice under the Dox treatment showed
improved glucose tolerance compared with the same mice
after the removal of Dox (Fig. 3B). Consistently, plasma
insulin levels after glucose administration were signiﬁ-
cantly higher under the Dox treatment compared with
after the removal of Dox (Fig. 3C). The insulin secretion at
high glucose concentration was signiﬁcantly increased in
the isolated islets of dnRXR Tg mice by Dox treatment,
suggesting that the suppression of RXR function led to the
increased insulin secretory response by glucose stimula-
tion (Fig. 4A). Moreover, we conﬁrmed that the expression
of a dnRXR enhanced the GSIS in a transgenic -cell line,
dnRXR-MIN6. Our ﬁndings suggest that RXR acts as a
negative regulator of the high-glucose response in -cells,
which was further supported by the negative effect of
9cRA on the GSIS at high glucose in isolated islets and also
in dnRXR-MIN6 cells (Figs. 4A and 5D). Such negative
effect of 9cRA was seen, even under the dnRXR overex-
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A
B
*
Glucose concentration (mM)
Insulin content  (n = 6 each)
Dox (-) Dox (+)
20
15
10
5
0
(µ µg)  
I
n
s
u
l
i
n
 
s
e
c
r
e
t
i
o
n
 
(
n
g
/
i
s
l
e
t
/
h
) 2.5
2.0
1.5
1.0
0.5
0
      Dox(-), 9cRA(-)
      Dox(+), 9cRA(-)
      Dox(-), 9cRA(+)
      Dox(+), 9cRA(+)
3                  9                  27
*
*
**
**
FIG. 4. Analysis of insulin secretion in the dnRXR Tg mice. Islets were
isolated from Dox-treated and -untreated dnRXR Tg mice and cultured
in the presence and absence of Dox, respectively (A). Insulin secretion
from isolated islets in response to different concentrations of glucose
is shown (n  5–6 each). The effect of 9cRA treatment on the GSIS was
also examined (A). For measurement of insulin content, dnRXR Tg
mice with or without 2 weeks of Dox treatment were killed, and their
pancreases were isolated (n  6 each) (B). Values are expressed as the
mean  SE. Statistical analyses were carried out by the Student t test.
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(Figs. 4A and 5D). It was probably due to incomplete
inhibition of the RXR function by the dominant-negative
form of RXR.
In contrast, the basal insulin secretion at 3 mmol/l
glucose from isolated islets or dnRXR-MIN6 cells was not
signiﬁcantly affected by the suppression of RXR (Fig. 4B).
In addition, the suppression of insulin secretion by 9cRA
treatment was seen only at high glucose for both isolated
islets and dnRXR-MIN6 cells (Figs. 4A and 5D). These
ﬁndings suggested that RXR might function to inhibit
excessive insulin release under high-glucose conditions.
These opposing results for insulin release between the
high- and low-glucose responses suggest that the function
of the RXR on -cells may change, depending on the
ambient glucose concentration. Thus, RXR may deeply
participate in the regulatory mechanisms of GSIS.
Although the mechanism of the inhibitory effect of RXR
is unknown, several reports suggest that RXR elicits
diverse effects in -cells by combining with different
dimerization partners. PPAR- agonists are reported to
prevent the impairment of the insulin secretory capacity
induced by oxidative stress and lipotoxicity (22). A recent
report showed that the combination of a PPAR- agonist
and an RXR agonist acted synergistically and led to
protection against lipotoxicity in -cells (23). Thus, the
activation of PPAR/RXR signaling protects -cells against
oxidative stress and apoptosis. LXR is another het-
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FIG. 5. Establishment of dnRXR-MIN6 cells and their GSIS. RT-PCR (A), Western blotting (B), and immunocytochemical analyses (C) were
performed to detect the expression of rtTA and RXRC2 in this cell line. Dox treatment of the dnRXR-MIN6 cells induced the expression of the
RXRC2 mRNA (A) and protein (B). Immunocytochemical analyses also showed the induction of the dnRXR by Dox treatment in the nuclei
of these cells (C). The scale bars represent 100 m. dnRXR-MIN6 cells were cultured with or without Dox for 4 days. 9cRA was added to the
medium for the last 2 days of culture. Insulin secretion was measured at different glucose concentrations (n  4 each) (D). Values are expressed
as the mean  SE. Statistical analyses were carried out by the Student t test. *P < 0.05, **P < 0.01. (A high-quality digital representation of this
ﬁgure is available in the online issue.)
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that, in contrast to PPAR/RXR, the activation of LXR/RXR
signaling inhibits cell proliferation and induces apoptosis
in -cells (26,27). Efanov et al. (28) showed that the LXR
agonist T0901317 enhances the glucose-induced insulin
release from MIN6 cells, but the addition of 9cRA inhibits
the effect of T0901317, especially on the insulin release
response to high glucose. Thus, the function of RXR may
be altered by its heterodimeric partner in -cells.
RXR forms heterodimers with various partners of the
nuclear hormone receptor family. To identify genes regu-
lated by RXRs, we performed an oligonucleotide microar-
ray analysis of dnRXR-MIN6 cells before and after
induction of the dnRXR. The results revealed a number
of genes that were upregulated or downregulated by the
Dox treatment (supplementary Tables 2 and 3, respec-
tively; Fig. 6). The downregulated genes included Stra6,
Hk1, Kcnk9, Nr2f6, Hes5, cMaf, and Mki67. Stra6 was ﬁrst
identiﬁed as a retinoic acid–stimulated gene, and it en-
codes a membrane receptor for retinol-binding protein
that mediates the cellular uptake of vitamin A (29). The
ﬁnding that this retinoic acid–stimulated gene was down-
regulated by dnRXR expression indicates that our dnRXR
Tg mouse system worked as expected.
Hk1 encodes hexokinase, which has a lower Km for
glucose than glucokinase, the major isozyme in -cells.
The expression levels of Hk1 might affect the insulin
secretion from dnRXR-MIN6 cells (30). Kcnk9 (Task3)
encodes an acid-sensitive member of the two-pore-domain
background K
	 (K2P) channel family (31). K2P channels
contribute to the resting membrane potential by allowing
K
	 to leak out of the cell. Thus, the downregulation of
Kcnk9 might inﬂuence the insulin secretion.
cMaf is one of the large-Maf transcription factor family
genes, which also includes MafA and MafB. These factors
are reported to be expressed in -cells and to function as
transcription factors for the insulin gene (32). Nr2f6
(Ear2) encodes an orphan nuclear receptor, which is an
RXR binding partner (33). However, the role of NR2F6 in
-cells has not been reported. Hes5 is an effector protein
in Notch signaling and belongs to the Hes family, as does
Hes1, whose role in -cells has been studied. The inhibi-
tion of Hes1 expression using small hairpin RNA reduces
the proliferation and dedifferentiation of -cells (34,35).
Another downregulated gene, Nkx6-2, encodes a transcrip-
tion factor that is required for endocrine development in
the pancreas (36).
Among the genes upregulated by the expression of the
dnRXR were those involved in transcription (Gtf2a2,
Gtf2h3, Trfp, Lsm1, Lsm8, Polr3k, and Cdca4), protein
synthesis (Rpl22, Rps27l, Rpl13Rps18, Rps25, Rpl15,
Nat5, and Senp3), signal transduction (Itpa), protein traf-
ﬁcking (Sec61b, Vps22, Lztr1, Arfgap3, Rab37, Fkbp4, and
Trappc3), and mitochondrial function (Ndufa4, Atp5j2,
Cyb561d1, Mrpl44, Mrps5, Slc25a11, and Cyb5). These
genes could contribute to the elevation of the secretory
capacity of -cells.
The Tet-On system, which provides a tissue-speciﬁc and
inducible expression of transgenes in animals, is suitable
for investigating the functions of genes that have not been
well characterized in vivo. Here, we successfully applied
the Tet-On system to express a dnRXR speciﬁcally in
-cells. Our data suggest that RXRs inhibit insulin secre-
tion from -cells at high glucose levels. In addition, our
DNA microarray analysis suggested several candidate
genes that might be involved in this regulation. Although
further studies on partners of RXRs and their target genes
are needed, our ﬁnding that RXRs have multiple functions
in the insulin secretion from -cells may lead to novel
therapeutic strategies for treating the impaired insulin
secretion in type 2 diabetes.
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